Oncology Drugs

A majority of cancer patients require chemotherapy treatment. Unfortunately for those patients, chemotherapy costs continue to escalate in the United States. The rising costs associated with chemotherapy can make treatment at times out of reach for even the most financially fortunate of patients.

The continued rise in costs are attributable to:

  • The increasing prevalence of cancer in an aging population;
  • The increasing number of available chemotherapy drugs and indications;
  • The increasing cost of newer drugs compared to the cost of the drugs that they replaced; and
  • Movement of treatment location from the office to the hospital outpatient setting.

Oncology Analytics applies an evidence-based approach to prior authorization of chemotherapy drugs to reduce undertreatment, overtreatment and inappropriate treatment of cancer patients. Oncology Analytics’ evidence-based, data-driven approach allows the clinician to be guided by high-quality, patient-specific derived information. Oncology Analytics’ board-certified oncologists and hematologists, in conjunction with Oncology Analytics’ board-certified oncology pharmacists, have developed protocols that collectively cover over 99 percent of patients’ cancer diagnoses. These protocols are based on evidence-based guidelines from nationally recognized authorities such as NCCN, ASCO and others.

Treating physicians use Oncology Analytic’s proprietary software, MATISTM, which provides them with an automatic authorization if their requested treatment is within recognized guidelines. Treatments requested that are outside of the guidelines receive further review from Oncology Analytic’s clinical team. The clinical team then collaborates with the physicians to ensure that the treatment requested is optimized to the individual patient. If additional review is still required, Oncology Analytics’ Distinguished Academic Advisory Board members provide guidance. Oncology Analytics’ goal is to never compromise patient care, which is accomplished by meeting the highest possible clinical standards while remaining cost-effective.

Source: Global Oncology Trend Report, IMS Institute 2015